Pulmotect
Pulmotect, Inc. is dedicated to harnessing the power of the innate immune system to develop inhaled therapeutics that provide immediate and effective protection against viral, bacterial, and fungal pathogens. Their lead product, PUL-042, has demonstrated safety and efficacy in clinical trials, with ongoing studies to assess its effectiveness in preventing respiratory complications and improving outcomes in at-risk populations.
Industries
Nr. of Employees
small (1-50)
Pulmotect
Patents
Products
Clinical-stage inhaled innate immune stimulant (pulmonary)
A clinical-stage inhaled therapeutic candidate formulated for aerosol or intranasal delivery that activates innate immune defenses in the lungs to reduce susceptibility to viral, bacterial and fungal respiratory infections; demonstrated tolerability in Phase I/IIa trials and exploratory antiviral activity in Phase II studies.
PUL-042
A clinical stage inhaled therapeutic that stimulates the innate immune system in the lung to provide immediate and effective protection against viral, bacterial, and fungal infections, including in immunosuppressed animal models.
Clinical-stage inhaled innate immune stimulant (pulmonary)
A clinical-stage inhaled therapeutic candidate formulated for aerosol or intranasal delivery that activates innate immune defenses in the lungs to reduce susceptibility to viral, bacterial and fungal respiratory infections; demonstrated tolerability in Phase I/IIa trials and exploratory antiviral activity in Phase II studies.
PUL-042
A clinical stage inhaled therapeutic that stimulates the innate immune system in the lung to provide immediate and effective protection against viral, bacterial, and fungal infections, including in immunosuppressed animal models.
Expertise Areas
- Clinical trial management for respiratory therapeutics
- Inhaled formulation and aerosol delivery
- Innate immunity–based therapeutic development
- Preclinical infectious disease models
Key Technologies
- Aerosolized/inhalation delivery
- Intranasal spray delivery
- Innate immune stimulation
- Preclinical respiratory infection models